Compare Cronos Group Inc (CRON) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs UiPath Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while UiPath Inc trades at $11.98 (market cap $6.19B). The key difference: UiPath Inc is far larger — about 6.1× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| CRON | PATH | |
|---|---|---|
Market Cap | $1.02B | $6.19B |
Sector | Health | Technology |
52-Week High | $3.27 | $19.29 |
52-Week Low | $1.95 | $9.38 |
Enterprise Value | $203.29M | $4.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
UiPath (PATH) trades at $11.85, up 1.46% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent earnings show mixed results with Q1 2026 missing expectations but strong gross margins of 83.01% highlight operational efficiency. Analyst consensus price target sits at $13.33 with 25% buy ratings.
PATH presents a compelling turnaround story with accelerating revenue growth and path to profitability. Key opportunities include agentic AI adoption through Maestro platform and expanding enterprise automation. Risks include execution challenges in AI monetization, competitive pressures, and the stock's premium valuation multiples requiring sustained growth delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
